3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low‐Density Lipoproteins and Increasing Their Uptake by Macrophages

      research-article
      , PhD 1 , , PhD 1 , , PhD 1 , , PhD 1 , , PhD 2 , , MSc 2 , , MSc 2 , , PhD 3 , , MSc 4 , , PhD 4 , , PhD 5 , , PhD 6 , , PhD 7 , , MD 3 , , PhD 2 , , , PhD 1 ,
      Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
      John Wiley and Sons Inc.
      Ashwell‐Morell receptor, low‐density lipoprotein, macrophage, neuraminidase, sialic acid, Animal Models of Human Disease, Lipids and Cholesterol, Inflammation, Atherosclerosis, Genetically Altered and Transgenic Models

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Chronic vascular disease atherosclerosis starts with an uptake of atherogenic modified low‐density lipoproteins (LDLs) by resident macrophages, resulting in formation of arterial fatty streaks and eventually atheromatous plaques. Increased plasma sialic acid levels, increased neuraminidase activity, and reduced sialic acid LDL content have been previously associated with atherosclerosis and coronary artery disease in human patients, but the mechanism underlying this association has not been explored.

          Methods and Results

          We tested the hypothesis that neuraminidases contribute to development of atherosclerosis by removing sialic acid residues from glycan chains of the LDL glycoprotein and glycolipids. Atherosclerosis progression was investigated in apolipoprotein E and LDL receptor knockout mice with genetic deficiency of neuraminidases 1, 3, and 4 or those treated with specific neuraminidase inhibitors. We show that desialylation of the LDL glycoprotein, apolipoprotein B 100, by human neuraminidases 1 and 3 increases the uptake of human LDL by human cultured macrophages and by macrophages in aortic root lesions in Apoe −/− mice via asialoglycoprotein receptor 1. Genetic inactivation or pharmacological inhibition of neuraminidases 1 and 3 significantly delays formation of fatty streaks in the aortic root without affecting the plasma cholesterol and LDL levels in Apoe −/− and Ldlr −/− mouse models of atherosclerosis.

          Conclusions

          Together, our results suggest that neuraminidases 1 and 3 trigger the initial phase of atherosclerosis and formation of aortic fatty streaks by desialylating LDL and increasing their uptake by resident macrophages.

          Related collections

          Most cited references90

          • Record: found
          • Abstract: found
          • Article: not found

          Mechanisms of plaque formation and rupture.

          Atherosclerosis causes clinical disease through luminal narrowing or by precipitating thrombi that obstruct blood flow to the heart (coronary heart disease), brain (ischemic stroke), or lower extremities (peripheral vascular disease). The most common of these manifestations is coronary heart disease, including stable angina pectoris and the acute coronary syndromes. Atherosclerosis is a lipoprotein-driven disease that leads to plaque formation at specific sites of the arterial tree through intimal inflammation, necrosis, fibrosis, and calcification. After decades of indolent progression, such plaques may suddenly cause life-threatening coronary thrombosis presenting as an acute coronary syndrome. Most often, the culprit morphology is plaque rupture with exposure of highly thrombogenic, red cell-rich necrotic core material. The permissive structural requirement for this to occur is an extremely thin fibrous cap, and thus, ruptures occur mainly among lesions defined as thin-cap fibroatheromas. Also common are thrombi forming on lesions without rupture (plaque erosion), most often on pathological intimal thickening or fibroatheromas. However, the mechanisms involved in plaque erosion remain largely unknown, although coronary spasm is suspected. The calcified nodule has been suggested as a rare cause of coronary thrombosis in highly calcified and tortious arteries in older individuals. To characterize the severity and prognosis of plaques, several terms are used. Plaque burden denotes the extent of disease, whereas plaque activity is an ambiguous term, which may refer to one of several processes that characterize progression. Plaque vulnerability describes the short-term risk of precipitating symptomatic thrombosis. In this review, we discuss mechanisms of atherosclerotic plaque initiation and progression; how plaques suddenly precipitate life-threatening thrombi; and the concepts of plaque burden, activity, and vulnerability. © 2014 American Heart Association, Inc.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Enzymatic determination of total serum cholesterol.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

              Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels. Copyright 2004 Massachusetts Medical Society
                Bookmark

                Author and article information

                Contributors
                ccairo@ualberta.ca
                alexei.pchejetski@umontreal.ca
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                06 February 2021
                16 February 2021
                : 10
                : 4 ( doiID: 10.1002/jah3.v10.4 )
                : e018756
                Affiliations
                [ 1 ] Departments of Pediatrics and Biochemistry Sainte‐Justine University Hospital Research Center University of Montreal Quebec Canada
                [ 2 ] Department of Chemistry University of Alberta Edmonton Alberta Canada
                [ 3 ] Departments of Medicine, Microbiology and Immunology McGill University Montreal Quebec Canada
                [ 4 ] Department of Chemistry Université du Québec à Montréal Montreal Quebec Canada
                [ 5 ] Institute of Human Morphology Moscow Russia
                [ 6 ] Miyagi Cancer Center Research Institute Natori Miyagi Japan
                [ 7 ] Institut National de la Santé et de la Recherche Médicale UMR 1048 Institute of Metabolic and Cardiovascular Diseases Toulouse France
                Author notes
                [*] [* ] Correspondence to:

                Alexey V. Pshezhetsky, PhD, Sainte‐Justine University Hospital Research Center, 3175 Cote Ste‐Catherine, Montreal, QC H3T 1C5, Canada. E‐mail: alexei.pchejetski@ 123456umontreal.ca and Christopher W. Cairo, PhD, Department of Chemistry, 4‐082 Centennial Centre for Interdisciplinary Science, University of Alberta, Edmonton, AB T6G 2G2, Canada. E‐mail: ccairo@ 123456ualberta.ca

                [*]

                Dr Demina and Dr Smutova contributed equally to this work as co–first authors.

                Author information
                https://orcid.org/0000-0001-8877-880X
                https://orcid.org/0000-0003-3363-8708
                https://orcid.org/0000-0002-6612-1062
                Article
                JAH35870
                10.1161/JAHA.120.018756
                7955353
                33554615
                4e3a3a26-88ac-43be-b1da-9ef39adab9c1
                © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 25 August 2020
                : 17 November 2020
                Page count
                Figures: 7, Tables: 1, Pages: 23, Words: 15035
                Funding
                Funded by: Canadian Glycomics Network , open-funder-registry 10.13039/501100009056;
                Funded by: Canadian Institutes of Health Research , open-funder-registry 10.13039/501100000024;
                Award ID: PJT‐148863
                Funded by: Natural Sciences and Engineering Research Council of Canada , open-funder-registry 10.13039/501100000038;
                Funded by: Canada Research Chair
                Funded by: Russian Science Foundation , open-funder-registry 10.13039/501100006769;
                Award ID: 20‐15‐00264
                Categories
                Original Research
                Original Research
                Coronary Heart Disease
                Custom metadata
                2.0
                February 16, 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.7 mode:remove_FC converted:15.02.2021

                Cardiovascular Medicine
                ashwell‐morell receptor,low‐density lipoprotein,macrophage,neuraminidase,sialic acid,animal models of human disease,lipids and cholesterol,inflammation,atherosclerosis,genetically altered and transgenic models

                Comments

                Comment on this article